Grade 3–4 TEAEs (overall population)Avelumab + axitinib: 71% (most common: hypertension [26%]; diarrhoea [7%]; increased ALT [6%]; PPES [6%])Sunitinib: 72% (most common: hypertension [17%]; anaemia [8%]; neutropenia [8%]; thrombocytopenia [6%]; decreased neutrophils [6%]; decreased platelets [5%]). This evidence concerns the gene GPT and neutropenia.